6 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
Follow Hyponatremia: new trials by email Literature Review of Hyponatremia trials Research Report on Hyponatremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia Tolvaptan - Hyponatremia | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | 2016-04-22 | 2020-04-17 |
| Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia Tolvaptan - Hyponatremia | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | 2015-09-22 | 2018-09-26 |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia Conivaptan hydrochloride, Placebo - Hyponatremia | Phase 3 | Terminated | Cumberland Pharmaceuticals | 4 | 2012-02-01 | 2016-03-01 |
| Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia tolvaptan, Fluid Restriction - Hyponatremia, Dilutional Hyponatremia | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 124 | 2010-10-01 | 2014-10-30 |
| Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF) conivaptan, placebo - Hyponatremia, Acute Decompensated Heart Failure | Phase 3 | Terminated | Cumberland Pharmaceuticals | 9 | 2009-04-01 | 2014-05-15 |
| A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia Satavaptan, placebo - Hyponatremia, Inappropriate ADH Syndrome | Phase 3 | Terminated | Sanofi | 2 | 2008-07-01 | 2016-05-26 |
Inappropriate ADH Syndrome (2) · Metabolic Diseases (2) · Edema (1) · Water-Electrolyte Imbalance (1)
Nutritional and Metabolic Diseases (6) · Water-Electrolyte Imbalance (5) · Metabolic Diseases (4) · Brain Diseases (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Hypothalamic Diseases (2) · Nervous System Diseases (2) · Pituitary Diseases (2) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Tolvaptan (3) · conivaptan (2) · satavaptan (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Cumberland Pharmaceuticals (2) · Sanofi (1)
United States (5) · Italy (2) · United Kingdom (2) · Belgium (1) · Colombia (1) · Czechia (1) · Germany (1) · India (1) · Romania (1) · Spain (1)
Art Wheeler, MD (2) · Ann Dandurand, MD (1)